Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
4.000
+0.150 (3.90%)
Aug 21, 2026, 4:00 PM EDT - Market closed

Nasus Pharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Income
-10.13-4.9-1.08-1.15-2.04
Net Income
-10.55-5.86-1.53-1.05-1.71
Earnings Per Share
-1.07-0.73-0.22-0.20-0.25
EPS Growth
-----

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
11.824.290.280.190.15
Total Debt
0.10.121.82.461.57
Net Cash (Debt)
11.724.17-1.52-2.26-1.42
Net Cash Growth
181.07%----
Net Cash Per Share
1.190.52-0.22-0.32-0.21

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-10.52-4.92-0.67-1.03-1.21
Capital Expenditures
-0.02-0.01---
Free Cash Flow
-10.54-4.93-0.67-1.03-1.21
Free Cash Flow Growth
-----

Valuation

Selected indicators aren't available for this stock.